This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Upadacitinib ranked first for UC induction in network meta-analysis
Interleukin-23 p19 inhibitors ranked most favorably for serious adverse events and discontinuations across 33 trials, though the authors rated confidence in the safety estimates as lower.
-
11/06/2026